www jilibet www jilibet comcom
Cowboys win wild one vs. Commanders to halt five-game slideCARLSBAD, Calif. , Dec. 19, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved TRYNGOLZATM (olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a rare, genetic form of severe hypertriglyceridemia (sHTG) that can lead to potentially life-threatening acute pancreatitis (AP). TRYNGOLZA is the first-ever FDA-approved treatment that significantly and substantially reduces triglyceride levels in adults with FCS and provides clinically meaningful reduction in AP events when used with an appropriate diet (≤20 grams of fat per day). TRYNGOLZA is self-administered via an auto-injector once monthly. Experience the full interactive Multichannel News Release here: https://www.multivu.com/ionis-pharmaceuticals/9295551-en-tryngolza-olezarsen-fda-approval "Today's FDA approval of TRYNGOLZA heralds the arrival of the first-ever FCS treatment in the U.S. – a transformational moment for patients and their families. For the first time, adults with FCS can now access a treatment that substantially reduces triglycerides and the risk of debilitating and potentially life-threatening acute pancreatitis," said Brett P. Monia , Ph.D., chief executive officer, Ionis. "We are proud of our long-standing partnership with the FCS community and are grateful to the patients, families and investigators who participated in our clinical studies, enabling Ionis to make this new treatment a reality. The FDA approval of TRYNGOLZA is also a pivotal moment for Ionis, representing our evolution into a fully integrated commercial-stage biotechnology company – a goal we set out to achieve five years ago. With our rich pipeline of potentially life-changing medicines, we expect TRYNGOLZA to be the first in a steady cadence of innovative medicines we will deliver independently to people living with serious diseases." The FDA approval was based on positive data from the global, multicenter, randomized, placebo-controlled, double-blind Phase 3 Balance clinical trial in adult patients with genetically identified FCS and fasting triglyceride levels ≥880 mg/dL. In the Balance study, TRYNGOLZA 80 mg demonstrated a statistically significant placebo-adjusted mean reduction in triglyceride levels of 42.5% from baseline to six months (p=0.0084). Reductions from baseline to 12 months were further improved, with TRYNGOLZA achieving a placebo-adjusted 57% mean reduction in triglycerides. TRYNGOLZA also demonstrated a substantial, clinically meaningful reduction in AP events over 12 months; one patient (5%) experienced one episode of AP in the TRYNGOLZA group compared with seven patients (30%) who experienced 11 total episodes of AP in the placebo group. TRYNGOLZA demonstrated a favorable safety profile. The most common adverse reactions (incidence >5% of TRYNGOLZA-treated patients and at a >3% higher frequency than placebo) were injection site reactions (19% and 9%, respectively), decreased platelet count (12% and 4%, respectively) and arthralgia (9% and 0%, respectively). Results from the Phase 3 Balance study were previously published in The New England Journal of Medicine (NEJM). "With no treatment options previously available, we were limited to relying only on extremely strict diet and lifestyle changes as the sole preventative treatment option," said Alan Brown , M.D., FNLA, FACC, FAHA, clinical professor of medicine, Rosalind Franklin University of Medicine and Science ; Balance trial investigator. "The FDA approval of TRYNGOLZA is an important moment for people living with FCS, their families and physicians who now, for the first time, have a treatment that significantly lowers triglycerides and decreases the risk of potentially life-threatening acute pancreatitis events, as an adjunct to a low-fat diet. I am excited to have a medicine I can prescribe to my patients that has been shown to change the course of their disease." FCS is a rare, genetic, potentially life-threatening form of sHTG that prevents the body from breaking down fats and severely impairs the body's ability to remove triglycerides from the bloodstream due to an impaired function of the enzyme lipoprotein lipase (LPL). While healthy levels for adults are below 150 mg/dL, people with FCS often have triglyceride levels of more than 880 mg/dL and often have a history of pancreatitis. Those living with FCS have a high risk of potentially fatal AP, which is a painful inflammation of the pancreas, and chronic health issues such as fatigue and severe, recurrent abdominal pain. People living with FCS can also experience psychological and financial stress, which can significantly impact their quality of life. In the U.S., FCS is estimated to impact up to approximately 3,000 people, the vast majority of whom remain undiagnosed. "As a rare and difficult to diagnose disease, FCS has a profound impact on the lives of patients and families. Many people living with FCS have experienced severe pain their whole lives – sometimes so intense they require lengthy hospitalization stays – and struggle through life with daily fatigue, nausea, brain fog and stomach pain," said Lindsey Sutton Bryan , co-founder and co-president, FCS Foundation. "Until now, our treatment options have been limited, relying on diet alone to try to manage triglyceride levels and keep acute pancreatitis attacks at bay. For the first time, adults with FCS have seen their hope for a treatment become a reality." TRYNGOLZA will be available in the U.S. before year end. Ionis is committed to helping people access the medicines they are prescribed and will offer a suite of services designed to meet the unique needs of the FCS community through Ionis Every StepTM. As part of Ionis Every Step , patients and healthcare providers will have access to services throughout the treatment journey provided by dedicated Patient Education Managers and Ionis Every Step Case Managers, including insurance and affordability support, as well as services and resources, such as disease and nutrition education. Visit TRYNGOLZA.com for more information. TRYNGOLZA was reviewed by the FDA under Priority Review and had previously been granted Fast Track designation for the treatment of FCS, Orphan Drug designation and Breakthrough Therapy designation. Olezarsen is undergoing review in the European Union and regulatory filings in other countries are planned. Olezarsen is currently being evaluated in three Phase 3 clinical trials – CORE, CORE2 and ESSENCE – for the treatment of sHTG. Olezarsen has not been reviewed or approved for the treatment of sHTG by regulatory authorities. Webcast Ionis will hold a webcast today at 6:45pm ET to discuss the FDA approval. Interested parties may access the webcast here . A webcast replay will be available for a limited time. About TRYNGOLZATM (olezarsen) TRYNGOLZATM (olezarsen) was approved by the U.S. Food and Drug Administration as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). TRYNGOLZA is an RNA-targeted medicine designed to lower the body's production of apoC-III, a protein produced in the liver that is a key regulator of triglyceride metabolism. It is the only treatment currently indicated in the U.S. for FCS, a potentially life-threatening disease. For more information about TRYNGOLZA, visit TRYNGOLZA.com . IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS TRYNGOLZA is contraindicated in patients with a history of serious hypersensitivity to TRYNGOLZA or any of the excipients in TRYNGOLZA. Hypersensitivity reactions requiring medical treatment have occurred. WARNINGS AND PRECAUTIONS Hypersensitivity Reactions Hypersensitivity reactions (including symptoms of bronchospasm, diffuse erythema, facial swelling, urticaria, chills and myalgias) have been reported in patients treated with TRYNGOLZA. Advise patients on the signs and symptoms of hypersensitivity reactions and instruct patients to promptly seek medical attention and discontinue use of TRYNGOLZA if hypersensitivity reactions occur. ADVERSE REACTIONS The most common adverse reactions (incidence >5% of TRYNGOLZA-treated patients and >3% higher frequency than placebo) were injection site reactions, decreased platelet count and arthralgia. Please see full Prescribing Information for TRYNGOLZA. About Familial Chylomicronemia Syndrome (FCS) FCS is a rare, genetic disease characterized by extremely elevated triglyceride levels. It is caused by impaired function of the enzyme lipoprotein lipase (LPL). Because of limited LPL production or function, people with FCS cannot effectively break down chylomicrons, lipoprotein particles that are 90% triglycerides. FCS is estimated to impact up to approximately 3,000 people in the U.S. People living with FCS are at high risk of acute pancreatitis (AP) in addition to other chronic health issues such as fatigue and severe, recurrent abdominal pain. People living with FCS are sometimes unable to work, adding to the burden of disease. About the Balance Study Balance is a global, multicenter, randomized, double-blind, placebo-controlled Phase 3 study evaluating the efficacy and safety of olezarsen in patients with FCS at six and 12 months. The primary endpoint was the percent change from baseline in fasting triglyceride levels at six months compared to placebo. Secondary endpoints included percent changes in triglyceride levels at 12 months, percent changes in other lipid parameters and adjudicated acute pancreatitis event rates over the treatment period. Following treatment and the end-of-trial assessments, patients were eligible to enter an open-label extension study to continue receiving olezarsen once every four weeks. About Ionis Pharmaceuticals, Inc. For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis has discovered and developed six marketed medicines for serious diseases, including breakthrough medicines for neurologic and cardiovascular diseases. Ionis has a leading pipeline in neurology, cardiology and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter) , LinkedIn and Instagram . Ionis Forward-Looking Statements This press release includes forward-looking statements regarding Ionis' business and the therapeutic and commercial potential of TRYNGOLZA, Ionis' technologies and other products in development. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, including but not limited to those related to our commercial products and the medicines in our pipeline, and particularly those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. Except as required by law, we undertake no obligation to update any forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended Dec. 31, 2023 , and most recent Form 10-Q, which are on file with the SEC. Copies of these and other documents are available at www.Ionis.com . Ionis Pharmaceuticals® and TRYNGOLZATM are trademarks of Ionis Pharmaceuticals, Inc. Ionis Investor Contact: D. Wade Walke , Ph.D. info@ionis.com 760-603-2331 Ionis Media Contact: Hayley Soffer media@ionis.com 760-603-4679 View original content: https://www.prnewswire.com/news-releases/tryngolza-olezarsen-approved-in-us-as-first-ever-treatment-for-adults-living-with-familial-chylomicronemia-syndrome-as-an-adjunct-to-diet-302336747.html SOURCE Ionis Pharmaceuticals, Inc.
None
For airports, background music no longer is an afterthoughtSeibert misses an extra point late as the Commanders lose their 3rd in a row, 34-26 to the Cowboys
You can get this 40-inch LG UltraWide 5K monitor at $560 off if you hurryHusseini call for more collaboration to improve filmmaking traditionTejashwi Yadav, a key leader in the Rashtriya Janata Dal and former deputy chief minister of Bihar, announced on Sunday that the INDI alliance will assess its devastating setback in the Maharashtra assembly elections. In the 288-member state assembly, the opposition parties Congress, Shiv Sena (UBT), and Sharad Pawar's NCP (SP) managed to win a mere 16, 20, and 10 seats, respectively. In contrast, the BJP sizably secured 132 seats, with an additional 57 seats won by Eknath Shinde's Shiv Sena and 41 by NCP. Tejashwi Yadav, accompanied by his father Lalu Prasad Yadav, visited Peetambara Peeth, a renowned Shakti Peeth, for spiritual intervention. Expressing optimism, Yadav affirmed, "We have won in Jharkhand and will evaluate the causes behind our defeat in Maharashtra. Nevertheless, we are certain of our victory in the 2025 Bihar elections." The duo also paid their respects at the Van Khandeshwar temple of Lord Shiva. (With inputs from agencies.)Final regular-season games loom large in determining conference championship matchups
Sex Work the American Way
Hayleys Fentons Limited announced the opening of its inaugural Experience Centre located at Nawala Road, Nugegoda. This pioneering facility is designed to provide an immersive, hands-on exploration of the company’s cutting-edge solutions across 12 key sectors: Solar Power, ICT, Security and Communication, Audio-Visual Integration (AVI), Electrical and Lighting, Fire Safety Solutions, Air Conditioning and Ventilation, Plumbing and Gas, Facilities Management, Uninterrupted Power Supply and Battery Backups, Architectural Drawings and 3D Visualisation and Industrial Accessories Trading. Equipped with advanced technologies, the Experience Centre offers interactive product demonstrations, visually dynamic installations, and dedicated spaces for training, collaboration, and knowledge-sharing. It enables visitors to explore and engage with Hayleys Fentonsinnovative services in a hands-on environment. Sustainability takes centre stage at the Experience Centre featuring a BIPV (Building-Integrated Photovoltaic) roofing system by Hayleys Solar, symbolising the company’s dedication to renewable energy and green innovation. Hayleys Fentons Limited Managing Director Hasith Prematillake stated; “We are dedicated to delivering innovative, integrated services that meet our customers’ evolving needs. The Hayleys Fentons Experience Centre is a hub for collaboration, innovation, and growth. This one-stop destination allows customers to experience cutting edge solutions from some of the world’s best brands tailored to their specific requirements, in a cohesive and unified way – thus simplifying their decision-making process.
For “Hysteria!” actresses Anna Camp and Julie Bowen, horror is harder than comedy. “Horror is really hard actually because there is a fine line you have to walk; you have to make it feel grounded and you’re put in these extreme circumstances: You’re being possessed or pulled through the air, there’s nothing you can do to relate to that,” explained Camp of “Pitch Perfect” fame. “With comedy, you can have a relatable situation and go, ‘I’ve been in situations like that.’ There’s nothing you can compare (horror) to, so you have to use your imagination. I find it harder. Your imagination goes home with you at the end of the day. You’re still thinking crazy thoughts.” Bowen, best known for playing Claire Dunphy on “Modern Family,” agreed. “Comedy’s pretty binary because it’s like either you can make people laugh or you don’t. I can’t watch horror. I’m terrified, terrified! I am the easiest scare in the world, so as far as doing (horror), I want to make it as real as possible. It was hard because I had to be really, really crazy. There were times when I’d get back to my hotel room at 3 a.m., I didn’t want to be alone in my head,” said Bowen, laughing. Camp, Bowen, Royal Oak native Bruce Campbell (“Evil Dead”), showrunner David A. Goodman (“Futurama”), and Ypsilanti native/creator Matthew Scott Kane (“American Horror Story”) were promoting “Hysteria!” at the New York Comic Con in October. The horror series is streaming on Peacock. Set in the fictional Michigan town of Happy Hollow, the first episode of “Hysteria” begins with a popular quarterback’s disappearance and a pentagram is discovered on a garage door. As a result, rumors of the occult and satanic influence run rampant through the town. A trio of outcasts in a heavy metal band called Dethkrunch exploit this by rebranding themselves as a satanic metal band, which leads to them becoming the targets of the town’s witch hunt. “Something on my mind a lot in 2019 was we’re living in this post-factual age with social media. It seemed like decades and decades ago, you could trust the news. Now everything is in question. When lies end up getting disseminated as truth, that starts to warp people’s version of reality. Suddenly, they’re living in a world other people are not. That was going on in the world I was living in and I very quickly connected it to the 1980s satanic panic. It’s not really that different because people were saying Ozzy Osbourne, Jason Voorhees (of ‘Friday the 13th’), and the Smurfs were going to turn your kids into satanists and kill you in your sleep. That didn’t happen. It wasn’t true, but so many people got worked up into such a fervor over it, bad things happened. ... It was smoke without fire,” Kane said. “Disinformation is not new,” Campbell said. “Disinformation will tear a town apart.” Campbell portrays Happy Hollow Police Chief Ben Dandridge. “This guy’s a reasonable cop; he’s a rational person who doesn’t treat the teenagers like they’re idiots. It’s all very refreshing,” he said. “I want to play that guy again. I want cops to be that guy. I’m playing the cop (that) cops need to be. That’s my whole motivation for playing this guy: How would you like cops to be, especially the guy in charge, the chief of police? They’re lucky to have Chief Dandridge.” “It was truly an exciting moment when Bruce signed on,” Goodman said. By the end of the first episode, a supernatural phenomenon happens to Linda Campbell, played by Bowen. “Linda seems like one thing, then you realize she’s bananas. She’s either bananas or she’s possessed. Either way, it’s a complicated thing to play,” Bowen said. “With Julie, you can have your cake and eat it too,” Kane said. “She’s this fun, quirky mom. ... As the episode goes on, she’s pulled deeper into this thing and crazy stuff starts happening. That final act of the first episode was my favorite moment with her because this announced that this is not Claire Dunphy. We’re not doing that again; we’re pushing her as a performer. “Julie was so excited about doing stunts. She told us on many occasions she’s very sturdy and can take it. The same goes for Bruce and for Anna. We didn’t ask anyone to give us a flavor of the thing they did before. We cast people we loved so much (in their famous projects) that we wanted to give them the opportunity to do the exact opposite.” Added Bowen: “I got this script and was like, ‘Oh great. She’s a mom. How fun.’ I love moms. I’m a mom, but I felt this was not worth flying out of town to Georgia and being away from my kids. Then I got to the end of the pilot and was like, ‘She’s crazy!’ Is she possessed? There’s a lot more questions. It’s fun to just stretch again and do things I haven’t done in a while, which I found really exciting.” Kane said he felt lucky Bowen signed on at the beginning. “She was the first adult actor to sign on. That gave us such credibility to have a two-time Emmy-winning actor leading this show. Suddenly, it goes from this script from a relatively unknown writer into the new Julie Bowen show,” he said. It was the quality of the writing that attracted Camp, Bowen and Campbell to “Hysteria!” “I loved the script; it was incredibly well-written. It was immersed in the time period. It was such a good coming-of-age story, too — the feeling of being in high school again, being in the 1980s,” Camp said. “I talked to Matt who said my character (Tracy) was incredibly pivotal to the series and we’ll learn about why she is the way she is. So I was like, ‘I’d love to do this!’” For Campbell, the writing is everything. “A lot of times, I’ll get a script that could make the words interchangeable with every other character because the writing is very bland and just doesn’t have the detail you need. This was different. Every character was pretty distinct and pretty well-drawn,” he said. “It’s quality. It’s not a (expletive) show. It’s a real show that’s playing around with interesting themes. A lot of it is still relevant to this day.” “Hysteria!” has other Michigan connections, including University of Michigan alumnus Jonathan Goldstein (“Spider-Man: Homecoming”) and Dondero High School alumnus Jordan Vogt-Roberts (“Kong: Skull Island”), who both serve as executive producers. Kane explained why he set “Hysteria!” in Michigan. “You write what you know. I grew up in Ypsilanti, so that had a lot to do with it. More importantly, when you’re in a small town in the Midwest — somewhere like Michigan — these things don’t ever happen and word spreads fast and paranoia spreads quickly and (everything’s) blown out of proportion and takes up a lot of people’s minds,” he said. “Whether or not something is real doesn’t matter. It doesn’t matter if there are people willing to believe it does and willing it into the world. What does it matter if it’s objectively real or living rent-free in someone’s head?”Genocidal Chinese dictator Xi Jinping held extensive, fruitful meetings with socialist Brazilian President Luiz Inácio Lula da Silva on Wednesday that concluded with the countries agreeing to elevate their diplomatic ties to that of “Community for a Shared Brazil-China Future for a More Just World and More Sustainable Planet.” That elevation consisted in part of the signing of 37 different agreements, the Brazilian newspaper O Globo reported , that span “agricultural products, educational exchange, and technological cooperation in areas such as trade, investments, infrastructure, industry, energy, mining, finance, communications, sustainable development, tourism, sports, health, and culture.” The two leaders agreed to expand the scope of their cooperation as part of China’s Belt and Road Initiative (BRI), a global infrastructure plan in which China offers predatory loans to poor countries to be used to fund cost-prohibitive infrastructure projects. When the countries cannot pay the loans back, China uses the opportunity to seize the projects themselves or otherwise compromise the sovereignty of the country in question, as has happened to Sri Lanka and Zambia . Some reports indicate China also exploits BRI projects to gather intelligence in targeted countries. Lula, a radical leftist, has invested heavily in expanding China’s influence in his country since his first term in office began in 2003. In addition to joining the BRI, Lula helped found the BRICS coalition, an anti-American group initially consisting of China and Brazil alongside Russia, India, and South Africa. Lula served his first two terms from 2003 to 2011 and was repeatedly convicted on corruption charges related to a massive infrastructure fraud scheme known as “Operation Car Wash.” He won the 2022 presidential election after Brazil’s top court overturned his prison sentences on procedural grounds. “Chinese companies have been bidding for infrastructure projects and have been partners in ventures such as the construction of hydroelectric installations and railroads. This means jobs, income and sustainability for Brazil,” Lula declared in a speech alongside Xi on Wednesday. “Brazilian industries are also expanding their presence in China, such as WEG, Suzano and Randon. At the same time, agribusiness continues to ensure Chinese food security. Since 2017, Brazil has been China’s largest food supplier.” Xi declared the relationship between Brazil and China to be “at the best in its history” and celebrated the two countries for making “outstanding contributions to world peace and stability.” In reality, Beijing is a primary enabler of some of the most nefarious rogue regimes in the world, including Iran, North Korea, and Cuba, while Brazil under Lula has vocally opposed sanctions and other actions against Russia for its invasion of Ukraine. Brazil and China have united to pressure Ukraine to accept terms favorable to Russia in exchange for ending the invasion, which Lula celebrated in his remarks. “China and Brazil prioritize peace, diplomacy, and dialogue. Our common understanding of the Ukraine crisis is an example of our convergence on international security matters,” he said. Xi chose to emphasize the expansion of the BRI and Brazil’s support for China’s “core interests,” typically including China’s false claims to the nation of Taiwan as a renegade province. “Xi called on the two sides to firmly support each other on issues concerning core interests such as sovereignty, security and territorial integrity,” the state-run Global Times reported , “be strategic partners of mutual trust and set a good example of solidarity, cooperation, mutual benefit and common development for countries in the Global South.” The “Global South” is a term typically used to mean the world’s poor and developing countries; China includes itself as a leader of the “Global South” despite being the world’s second-largest economy and being located in the Northern Hemisphere. The provisions of the official declaration on elevating bilateral ties indeed mentions China’s false claims to Taiwan. “The Brazilian side reiterated that it firmly adheres to the One China principle, recognized that there is only one China in the world and that Taiwan is an inseparable part of Chinese territory,” the text read, “while the Government of the People’s Republic of China is the only legal government representing all of China.” “Brazil supports China’s efforts to achieve peaceful national reunification. The Chinese side expressed great appreciation in this regard,” it added. The declaration also listed “finance, infrastructure, supply chain development, investments, ecological transformation, science, and technology and innovation” as areas of cooperation. Xi is currently concluding a South America tour that began in Peru, where he helped inaugurate an incomplete deep-water port alongside President Dina Boluarte and attended the annual support of the Asia-Pacific Economic Cooperation (APEC) group. He then traveled to Rio de Janeiro to attend the G20 summit and concluded his trip with a stop in Brasilia for the official state visit to Brazil. The Chinese dictator was a dominant presence at both the APEC summit and the G20, particularly in the absence of any meaningful American leadership. Outgoing President Joe Biden attended both summits but made little impact and appeared to be routinely ignored or sidelined by the other participants. The G20 was nonetheless the site of significant discord, reports on the ground indicated, as many countries’ diplomats navigated apprehension about the return of President-elect Donald Trump to the White House. The ultimate joint statement from the summit avoided specific promises on many critical issues, opting instead to generally call for an end to hunger and war. Follow Frances Martel on Facebook and Twitter.
Carlsquare Advises Boomi on Acquisition of Data Integration Provider RiveryIt seems as if consumers can buy just about anything from Amazon . Now, you can add cars to that list. Can Amazon Autos become a go-to destination for car buyers, providing Amazon with a competitive edge in an area where Walmart has yet to establish a strong presence? While Walmart does sell and even buy cars through its Carsaver partnership, the company still relies on third parties to handle the bulk of the transaction process. This leaves an opportunity for Amazon to take a more direct approach, leveraging its vast ecosystem and tech-driven conveniences to elevate the car-buying experience. In an interview with PYMNTS, Michael Zakkour , Founder and Chief Strategist at 5 New Digital , explained that Amazon is trying to live up to its reputation as “The Everything Store” by creating Amazon Autos. “Amazon is banking on consumers’ familiarity and trust in the Amazon platform and seeing all of its features, like reviews and star ratings, applied to the car-buying process,” Zakkour noted. “It was strategically wise for Amazon to start with an exclusive partnership with Hyundai . This partnership gives Amazon a chance to learn about the auto industry, collect reams of data and better formulate how to disrupt the category and make online buying a significant purchase channel for cars.” Unlike Walmart’s Carsaver platform, which primarily serves as a middleman for car sales and does not provide the same end-to-end experience, Amazon’s direct entry into the market gives it an opportunity to redefine the online car-buying journey. Walmart’s approach involves facilitating sales through a third party, but Amazon’s ecosystem will integrate car-buying into its core platform, offering everything from purchasing and financing to delivery with the added benefits of Prime perks and Alexa integration. While the number of “100% pure, sight-unseen online car purchases is growing, they still pale in comparison to dealership sales,” he added. “ CarMax , Carvana and Vroom have made solid progress in the used car and B2B car sales spaces, while still not finding a mass audience for new car sales. I expect Amazon to deploy their usual playbook when entering a new category. That said, Amazon still has a lot of challenge to overcome, much as they found out with their purchase of Whole Foods and the rollout of Amazon Fresh stores in grocery.” Amazon’s entry into the used car market leverages its financial strength, advanced technology, and ecosystem synergies to gain a competitive edge over weaker rivals like Carvana and Vroom, Zakkour noted. By undercutting prices, simplifying the purchasing and delivery process and bundling cars with Prime perks and Alexa integrations, Amazon can offer unmatched convenience and value. Additionally, its strong brand reputation for customer service and reliability positions it to attract hesitant online car buyers and dominate the market. But, Zakkour added, “many buyers still prefer test drives and in-person experiences before purchasing a car. Amazon must address this with test-drive partnerships or similar solutions.” “Trusting an entirely online process for such a high-ticket purchase may take time. Cars are unlike books or electronics. They require specialized logistics for delivery, inspection, and registration. Managing returns or exchanges adds to this complexity.” With the brand power Amazon commands, it can challenge traditional auto sales and provide a more streamlined experience than what Walmart’s Carsaver platform offers. Combining consumer trust with technological innovation could give Amazon an edge in attracting a broader audience to its car-buying service, Zakkour added, setting it apart from Walmart’s current indirect approach. But Amazon will face competition on two fronts, Zakkour explained, adding, “Carvana and Vroom, though weaker financially, have existing infrastructure for online car sales. Automakers and dealerships invest heavily in improving their online capabilities. Amazon has disrupted and remade entire consumer product and service categories before, and I give them a fighter’s chance to do it again in online auto sales.” Meanwhile, consumer confidence could be a big advantage for Amazon, according to Arias Websterberry , CEO of WebsterBerry Marketing . “Amazon already has millions of users who associate the brand with convenience and reliability,” he explained to PYMNTS. “With the Amazon app, it’s incredibly easy to find competitive pricing, which gives them a strong edge in building consumer confidence as they expand into this new industry and offering.” Amazon’s logistics and delivery expertise, Websterberry added, is one of its biggest strengths. “They’ve completely revolutionized the global logistics system and are unmatched in getting products directly to consumers,” he said. “I’m really curious to see how they’ll streamline the delivery process for something as large and complex as a car. It will be fascinating to see how Amazon integrates this offering with their other services, like Prime and Alexa. Imagine scheduling a test drive through the Amazon app or even asking Alexa to remind you about car maintenance — it’s those kinds of integrations that could set them apart.” Amazon’s scale and “deep pockets give it clear advantages as it moves into online auto sales,” according to Nelson Pereira , Managing Partner, Transportation & Mobility at digital consultancy Publicis Sapient . “But cars aren’t like gadgets. A lot of buyers still want to kick the tires — literally — take a test drive, and yes, even negotiate in person. Add in trade-ins, after-sales service and warranty support, and it’s clear Amazon will have some gaps to fill.” This move will push the industry forward by better connecting with digital-first consumers, Pereira added, “but it won’t replace what exists today. For OEMs, the real opportunity is finding the right balance — offering the seamlessness, digital-first experience consumers expect while preserving the trust and touchpoints that make the car-buying journey unique. That’s where the future is headed.” Here’s a look at other notable developments from Amazon and Walmart in the past week: Amazon Highlights Amazon Revamps Packaging for Sustainability : Amazon is enhancing its packaging for devices like Echo , Kindle , and Fire TV to improve sustainability and recyclability. The company redesigned its packaging to include 30% more recycled fiber, reduced ink usage by 60%, and removed plastic bags in favor of water-based coatings and paper wraps. The changes are part of Amazon’s plan to reduce its environmental impact, including lowering packaging weight and eliminating plastic air pillows in deliveries. Amazon seeks to make its packaging easier to recycle, improve product accessibility with tactile QR codes, and meet its climate goals by decarbonizing its transportation network. Amazon Expands Delivery Network to Remote Areas of Mexico: Amazon’s logistics network in Mexico enables reliable delivery even to remote areas like Baja California Sur , a region with limited road access and dispersed communities. The process begins with products being shipped from fulfillment centers to a port , where they are ferried across the Gulf of California before being delivered by third-party carriers using various transport methods. This efficient system has allowed Amazon to expand its reach from 16 cities in 2015 to over 400 cities today, enhancing economic and social integration in underserved regions. Amazon Expands Delivery Network to Remote Areas of Mexico Walmart Highlights Walmart’s Fintech One to Raise $300 Million, Expand Services: Walmart’s FinTech arm, One , is set to raise $300 million through Ribbit Capital in 2025, with plans to relaunch its credit card offering after parting ways with Capital One . This funding will support the company’s expanding financial services portfolio, which now includes checking accounts, buy now, pay later (BNPL), and upcoming pay-by-bank features. With a customer base of 255 million, including many underbanked individuals, Walmart is leveraging its vast consumer data to offer integrated banking and payment solutions, creating opportunities for cross-selling and strengthening customer loyalty. Walmart Tests Body Cameras for Employees: Walmart launched a pilot program in some U.S. stores, equipping employees with body cameras to enhance worker safety and deter conflict. The cameras, which have been used widely in law enforcement, are being tested to help address escalating interactions with customers, particularly during the busy holiday season. While similar technologies have been used by smaller retailers for theft prevention, Walmart’s focus is on protecting employees rather than loss prevention. Signs notifying shoppers of the cameras’ presence have been spotted in some locations and company officials plan to evaluate the program before making any long-term decisions.
- Previous:
- Next: is jilibet legit or not
